-
How is survival prognosis predicted for urothelial cancer treatment?
Time of Update: 2022-02-24
Clinicopathological Characteristics A study reported by Chinese scholars at the 2021 EAU Congress[10] aimed to analyze the germline mutational pattern of cancer susceptibility genes and in the largest upper tract urothelial carcinoma (UTUC) cohort to date Explore their clinical relevance .
-
A rare case of bladder cancer with skin metastases, have you seen it?
Time of Update: 2022-02-24
In this case, pelvic lymphadenectomy and radiotherapy were performed in the past for cervical cancer, resulting in various lymphatic fistulas in the skin .
The prognosis for patients with skin metastases from bladder cancer is poor .
-
IMmotion151 research final OS results released
Time of Update: 2022-02-24
Main results The IMmotion151 final analysis evaluated 915 patients with metastatic renal cell carcinoma, with median ages of 62 and 60 years in the tislizumab plus bevacizumab and sunitinib groups, respectively .
-
Prof. Gang Guo: Clinical value and timing of cytoreductive nephrectomy for metastatic renal cancer
Time of Update: 2022-02-23
Application and role of CN in the era of targeted combination therapy Checkmate9ER study: subgroup analysis results stratified by prior nephrectomy Checkmate9ER study aims to evaluate nivolumab + cabozantinib vs sunitinib in advanced stage Efficacy in kidney cancer .
-
2021 Inventory of Prostate Cancer Research Progress in China
Time of Update: 2022-02-23
During the meeting, Professor Li Yonghong of Sun Yat-Sen University Cancer Center shared the articles published by Chinese researchers in prostate cancer-related fields in 2021 and recommended relevant research progress .
-
Dr. Cai Yi walks with "swollen": looking back on the past and making his own voice in the field of prostate cancer
Time of Update: 2022-02-23
Insufficient existing treatment plans , insufficient patient benefits, and urgent desire of doctors to improve diagnosis and treatment methods are the driving forces that drive the continuous clinical research in the field of prostate cancer and the development and renewal of more drugs .
-
Influence of prostatic prolapse into bladder (IPP) on postoperative positive margins and continence recovery
Time of Update: 2022-02-23
Introduction Robot-assisted laparoscopy and laparoscopic radical prostatectomy (LRP) are important methods for the treatment of localized and locally advanced prostate cancer . Intravesical Protrusi
-
Prof. Lei Wang: Comparison of first-line treatment regimens for metastatic hormone-sensitive prostate cancer—update and review
Time of Update: 2022-02-23
Updated Study Interpretation ARCHES is a double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) in patients with mHSPC .
-
my country's first ADC for the treatment of urothelial cancer is here!
Time of Update: 2022-02-23
As China's first self-developed antibody-drug conjugate (ADC) new drug, on June 8 last year, the first indication of vedicitumab for injection was approved for marketing, and it is suitable for at least two systems Chemotherapy in patients with HER2-overexpressing locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma .
-
Professor Tang Qi's "diagnosis" insights: Talking about the development of the concept of prostate cancer diagnosis and treatment under the new diagnostic technology
Time of Update: 2022-02-23
In this interview, Professor Tang Qi, deputy chief physician of the Department of Urology, Peking University First Hospital, was invited to introduce the application of new imaging technology in the clinical diagnosis and treatment of advanced prostate cancer, as well as the accurate diagnosis, staging and stratification.
-
Heavy balls to keep or cut?
Time of Update: 2022-02-23
Looking back over the past 15 years, all patients considered to be benign lesions by intraoperative rapid freezing pathological examination in our center were finally diagnosed as benign testicular tumors .
-
Clinical combat from onset to imaging manifestations, a comprehensive understanding of ureteral calculi!
Time of Update: 2022-02-23
Imaging manifestations of calculi often occur at the ureteral stenosis, and there are three common places: the transition of the renal pelvis and ureter, the intersection of the iliac vessels, and the uretero-vesical junction .
-
PSA kinetics can be used to monitor nmCRPC prognosis: PSA deep remission is associated with long-term clinical benefit
Time of Update: 2022-02-23
Table 2 PSA kinetics of molecular subtypes in the apalutamide group in the SPARTAN study Correlation between PSA remission and outcomes in patients treated with apalutamide PSA reduction ≥50% and deep PSA reduction ≥90% at 6 months of treatment Or PSA ≤0.
-
The Light of Sinopharm: The first domestic ADC drug Vidicitumab has been approved for a new indication
Time of Update: 2022-02-23
In July 2021, the marketing application for the second indication of Vidicitumab was accepted by the NMPA Center for Drug Evaluation (CDE) and was included in priority review for patients who have received systemic chemotherapy and have HER2 (2+ or 3+) (immunohistochemical results) in patients with locally advanced or metastatic urothelial carcinoma .
-
Paper Summary: Diagnosis and Treatment of Overactive Bladder in Children
Time of Update: 2022-02-23
Combination medication: Studies have found that oral oxybutynin 5-20mg/d or tolterodine 2-4mg/d combined with low-dose solifenacin (5-10mg/d) has a good effect in the treatment of refractory OAB in children.
-
Research in the field of urothelial cancer in China: 2021 transcript
Time of Update: 2022-02-23
During the "2022 Beijing Urinary Oncology Youth Forum", Professor Zhang Cuijian of Peking University First Hospital shared the published articles of Chinese researchers in the field of urothelial cancer (bladder cancer and upper urinary tract urothelial cancer) in 2021.
-
Professor Cui Feilun "claims" the male theory: talk about the clinical diagnosis and treatment of prostate cancer "intrigue" with androgens
Time of Update: 2022-02-23
"Safety with Medicine" is a humanistic case collection project cooperating with Beijing Chen Jumei Public Welfare Foundation and Yimaitong . The series of interviews with physicians in urology wil
-
Molecular Cancer Multi-unit cooperation of Southern Medical University, Zhao Shanchao/Feng Ninghan/Chen Zhesheng discovered potential therapeutic targets for prostate cancer
Time of Update: 2022-02-23
John's University published a joint communication online in Molecular Cancer (IF=27) entitled "Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR- 653-5p", which identified differentially expressed circRNAs by RNA sequencing .
-
JAMA sub-journal: New endocrine therapy can cause depression, how to evaluate clinically?
Time of Update: 2022-02-22
*Only for medical professionals to read reference Prostate cancer anti-androgen treatment needs to pay attention to this! Second-generation anti-androgens have brought hope to countless prostate canc
-
Professor Gou Xin, a famous guide in the guide: Thoroughly understand the guide - qualified doctors know it, and excellent doctors know it
Time of Update: 2022-02-22
. For patients, the promotion of standardization will help clinicians at all levels and hospitals to provide them with medical solutions that are recognized in the field and maximize potential benefits under the guidance of unified clinical guidelines and rigorous medical evidence-based , optimize the process of diagnosis and treatment, reduce direct and indirect treatment costs, bring deeper benefits and improve the quality of life .
